Tag Archives: Joseph Pantginis

Checkpoint Therapeutics (CKPT) Receives a Rating Update from a Top Analyst

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Checkpoint Therapeutics (CKPT – Research Report) today and set a price target of $15.00. The company’s shares closed last Wednesday at $2.07. According to TipRanks.com, Pantginis is a top 100

Applied Genetic Technologies (AGTC) Receives a Rating Update from a Top Analyst

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Applied Genetic Technologies (AGTC – Research Report), with a price target of $18.00. The company’s shares closed last Monday at $6.17. According to TipRanks.com, Pantginis

H.C. Wainwright Sticks to Its Buy Rating for Beyondspring (BYSI)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Beyondspring (BYSI – Research Report), with a price target of $46.00. The company’s shares closed last Monday at $18.64. According to TipRanks.com, Pantginis is a

H.C. Wainwright Reiterates Their Buy Rating on Aptose Biosciences (APTO)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aptose Biosciences (APTO – Research Report) today and set a price target of $9.00. The company’s shares closed last Friday at $6.81. According to TipRanks.com, Pantginis is a 5-star analyst

Analysts Are Bullish on Top Healthcare Stocks: Lineage Cell Therapeutics (LCTX), CytoDyn (CYDY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lineage Cell Therapeutics (LCTX – Research Report) and CytoDyn (CYDY – Research Report) with bullish sentiments. Lineage Cell Therapeutics (LCTX) In a

IMV (IMV) Receives a Rating Update from a Top Analyst

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on IMV (IMV – Research Report), with a price target of $13.00. The company’s shares closed last Friday at $2.95. According to TipRanks.com, Pantginis is a